What is SuviCa?
Founded in 2010, SuviCa operates at the intersection of molecular biology and drug discovery. The company is currently prioritizing the advancement of SVC112, a small molecule protein synthesis inhibitor currently undergoing pre-clinical evaluation. By targeting specific cellular pathways essential for tumor re-growth, SuviCa aims to overcome the resistance profiles often associated with traditional chemotherapy. This strategic focus positions the company as a critical player in the development of novel combination therapies, providing a robust pipeline for future clinical applications in the oncology sector.
How much funding has SuviCa raised?
SuviCa has raised a total of $1.5M across 1 funding round:
Grant
$1.5M
Grant (2015): $1.5M, investors not publicly disclosed
Key Investors in SuviCa
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for SuviCa?
With the recent capital deployment, SuviCa is poised to transition its lead candidate, SVC112, through the rigorous stages of pre-clinical validation and toward potential human clinical trials. The strategic roadmap emphasizes the optimization of its protein synthesis inhibition platform, which serves as the cornerstone of its therapeutic value proposition. As the company scales its research operations, the focus will remain on establishing partnerships with healthcare providers and pharmaceutical entities to validate the efficacy of its small molecule inhibitors in diverse cancer models. This phase of development is critical for establishing long-term viability in the competitive landscape of precision oncology.
See full SuviCa company page
